Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms

Somatic CALR mutations occur in approximately 70% of patients with JAK2 V617F-negative essential thrombocythemia (ET) and primary myelofibrosis (PMF). We evaluated the effects of the CALR mutant type and burden on the phenotype of CALR-mutated myeloproliferative neoplasms (MPN). Of the 510 patients with suspected or diagnosed MPN, all 49 patients detected with CALR mutations were diagnosed with ET (n = 32) or PMF (n = 17). The CALR mutant burden was significantly higher in PMF than in ET (45% vs. 34%), and type 1-like and type 2-like mutations were detected in 49% and 51% patients, respectively. Patients with MPN and type 2-like mutation showed a significantly higher median platelet count than those with type 1-like mutation. Particularly, patients with ET and type 2-like mutation had no thrombotic events, despite higher platelet counts. The effect of CALR mutant burden differed depending on the mutant type. A higher mutant burden tended to be associated with a cytopenic phenotype (i.e., lower hemoglobin levels and platelet counts) in patients with the type 1-like mutation and a proliferative hematological phenotype (i.e., higher platelet and neutrophil counts) in patients with the type 2-like mutation. This study suggests that the disease phenotype of MPN may be altered through CALR mutant burden and mutant type.

[1]  F. Fabris,et al.  Clinical effect of CALR allele burden in patients with essential thrombocythemia , 2021, Annals of Hematology.

[2]  N. Nagy,et al.  Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. , 2018, Leukemia research.

[3]  E. Padron,et al.  Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. , 2016, Hematology/oncology and stem cell therapy.

[4]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[5]  F. Al-Shahrour,et al.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. , 2016, Cancer discovery.

[6]  C. Pecquet,et al.  Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. , 2016, Blood.

[7]  M. Cazzola,et al.  Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms , 2015, Leukemia.

[8]  R. Gale,et al.  Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations. , 2015, Leukemia research.

[9]  A. Tefferi,et al.  The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. , 2014, Blood.

[10]  E. Solary,et al.  Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution , 2014, Leukemia.

[11]  A. Tordai,et al.  Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations , 2014, Haematologica.

[12]  M. Cazzola,et al.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. , 2014, Blood.

[13]  P. Guglielmelli,et al.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. , 2014, Blood.

[14]  A. Tefferi,et al.  Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact , 2014, Leukemia.

[15]  F. Passamonti,et al.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons , 2014, Leukemia.

[16]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[17]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[18]  P. Guglielmelli,et al.  JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment , 2011, Therapeutic advances in hematology.

[19]  H. Kreipe,et al.  JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. , 2009, Experimental hematology.

[20]  M. Michalak,et al.  Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. , 2009, The Biochemical journal.

[21]  M. Møller,et al.  The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis – impact on disease phenotype , 2007, European journal of haematology.

[22]  Paola Guglielmelli,et al.  Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. , 2007, Blood.